The Biospecimen Core (Core B) provides part of the infrastructure support for Projects 1 - 4. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The Biospecimen Core is also involved in the maintenance of a large series of prostate cancer xenograft lines developed by Core investigators. These xenografts are used for proposed studies by the POI investigators and each study is overseen by Core personnel. Overall, the operations of this Core group into 4 components: 1. Specimen acquisition, processing, quality control, storage and accessioning into databases; 2. A prostate cancer xenograft maintenance, development and study program. 3. Laboratory services, including interpretation of tissues and tissue localization studies by a urologic pathologist, immunohistochemistry (IHC), quantitative RT-PCR, and immunoassays, i.e, PSA, and tissue culture. The Core will also perform pre-clinical studies using our xenograft resources;and 4. An administrative program to obtain samples from minority patients, prioritize the distribution of specimens, conduct a quality control program, and to ensure patient confidentiality and compliance with IRB requirements. The performance of each of the research projects detailed in this program project mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The investigators directing the Biospecimen Core also make it a policy to provide excess prostate cancer specimen resources to POI collaborators and to non-P01 investigators on a world-wide basis. Overall, the Biospecimen Core is a critical component of this P01 program project.

Public Health Relevance

The Biospecimen Core is not hypothesis driven yet it is an essential component of this POI that enables the investigative teams to conduct hypothesis driven projects. Without adequate specimens and tumor models, both in quantity and quality, the science conducted by these investigators cannot be robust. The Biospecimen Core assures quality research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Damodarasamy, Mamatha; Vernon, Robert B; Chan, Christina K et al. (2015) Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. In Vitro Cell Dev Biol Anim 51:50-8
Chen, Eddy J; Sowalsky, Adam G; Gao, Shuai et al. (2015) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 21:1273-80
Sowalsky, Adam G; Xia, Zheng; Wang, Liguo et al. (2015) Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res 13:98-106
Tamae, Daniel; Mostaghel, Elahe; Montgomery, Bruce et al. (2015) The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact 234:332-8
Jehle, Katja; Cato, Laura; Neeb, Antje et al. (2014) Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. J Biol Chem 289:8839-51
Hsieh, Chen-Lin; Fei, Teng; Chen, Yiwen et al. (2014) Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A 111:7319-24
Cao, Bo; Qi, Yanfeng; Zhang, Guanyi et al. (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5:1646-56
He, Housheng Hansen; Meyer, Clifford A; Hu, Sheng'en Shawn et al. (2014) Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification. Nat Methods 11:73-8
Penning, Trevor M (2014) Androgen biosynthesis in castration-resistant prostate cancer. Endocr Relat Cancer 21:T67-78
Thadani-Mulero, Maria; Portella, Luigi; Sun, Shihua et al. (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 74:2270-82

Showing the most recent 10 out of 24 publications